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Abstract 
 MDM2-MDMX complexes bind the p53 tumor suppressor protein, inhibiting 
p53’s transcriptional activity and targeting p53 for proteasomal degradation. 
Inhibitors that disrupt binding between p53 and MDM2 efficiently activate a p53 
response although their use in the treatment of cancers that retain wild type p53 may 
be limited by on-target toxicities due to p53 activation in normal tissue. Guided by a 
novel crystal structure of the MDM2-MDMX-E2(UbcH5B)–ubiquitin complex, we 
designed MDM2 mutants that prevent E2–ubiquitin binding without altering the 
RING domain structure. These mutants lose MDM2’s E3 activity, but retain the 
ability to limit p53's transcriptional activity and allow cell proliferation. Cells 
expressing these mutants responded more quickly to cellular stress than cells 
expressing wild type MDM2. Targeting the MDM2 E3 ligase activity could widen the 
therapeutic window of p53 activation in tumors, since rapid p53 induction can be 
achieved while basal p53 control by MDM2 is maintained. 
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Introduction 
The p53 tumor suppressor protein is induced in response to various types of 
oncogenic stress, functioning to arrest cell proliferation and induce cell death. 
Numerous mechanisms to control p53 have evolved, with a key role for the related 
RING domain proteins MDM2 and MDMX.  In mice, deletion of either MDM2 or 
MDMX results in early embryonic lethality due to uncontrolled p53 activation1-7. 
In healthy unstressed cells, MDM2 is primarily localized in the nucleus where 
it binds and inhibits p53, partly by ubiquitinating p53 and targeting it for proteasomal 
degradation8. The MDM2 RING domain is necessary for ubiquitin ligase (E3) activity 
and dimerization with itself or the RING domain of MDMX. Although MDMX can 
homodimerize at micro-molar concentration in vitro9, in cells, MDMX does not 
homodimerize and possesses no intrinsic E3 activity10-13. However, MDM2 and 
MDMX form an active E3 heterodimer, and some studies suggest this complex is the 
physiologically relevant ligase. MDM2’s E3 activity also contributes to 
transcriptional repression by ubiquitinating histones within promoters14. Furthermore, 
interactions between MDM2 and p53 can also directly inhibit the transcription factor 
function of p53 by altering interactions with other components of the transcriptional 
machinery15-17. In addition to a requirement to bind p53, other functions of MDM2 are 
important for the control of p53 activity. 
Mutations that prevent MDM2 RING domain homo- or heterodimerization 
lead to the loss of E3 activity and a failure to restrain p53 function6, 7, 18. The C-
terminal tail of MDM2 is also important for E3 activity, although this function can be 
provided by MDMX in vitro19, 20. Interestingly, in vivo an MDM2 tail mutant 
controlled p53 activity sufficiently to allow for normal development, despite 
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accumulation of p53 above basal levels in some tissues21. These results suggest that 
MDM2 can control p53 through degradation-independent mechanisms.  
The induction of p53 in response to stress is accompanied by the inhibition of 
MDM2, leading to the stabilization of transcriptionally active p53. Defects in the 
ability to inactivate MDM2 are frequently seen in cancers that retain wild type p53, 
and in which small molecule inhibitors of MDM2 may have a therapeutic benefit22. 
Several drugs that target the binding of p53 to MDM2 have been developed23-25 and 
show excellent specificity in stabilizing and activating p53. However, on-target 
toxicities including thrombocytopenia and neutropenia appear to limit the efficacy 
and utility of these compounds26, 27.  
Previous studies have shown that the RING domain of MDM2 functions to 
recruit E2 ubiquitin-conjugating enzyme thioesterified with ubiquitin (E2~Ub; ~ 
indicates thioester bond) and facilitate ubiquitination28, 29. We have solved the crystal 
structure of MDM2-MDMX RING domain heterodimer bound to E2(UbcH5B) 
covalently linked to ubiquitin (UbcH5B–Ub; – indicates covalent bond) and generated 
MDM2 mutants that retain RING domain integrity but do not interact with UbcH5B–
Ub. While these mutants are unable to ubiquitinate and degrade p53, they retain the 
ability to limit p53’s activity.  
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Results 
Structure of MDM2-MDMX RING domain bound to UbcH5B–Ub 
To understand how MDM2 RING domain binds and activates E2~Ub for 
catalysis, we assembled both MDM2 RING homodimer (MDM2RH; MDM2 428-C) 
and MDM2-MDMX RING heterodimer (MDM2R-MDMXR; MDM2 428-C and 
MDMX 427-C) in complex with UbcH5B–Ub for crystallization. UbcH5B–Ub 
complex was obtained by mutating UbcH5B’s C85 to a lysine to form an isopeptide 
bond with the C-terminal glycine of Ub30, 31. Only MDM2R-MDMXR-UbcH5B–Ub 
complex yielded diffracting crystals and the structure was determined to 2.16 Å (Fig. 
1a-c and Table 1).  
There are two copies of MDM2R-MDMXR-UbcH5B–Ub complex in the 
asymmetric unit (r.m.s deviation of 0.29 Å for C atoms). In both copies, MDM2R 
binds both UbcH5B and Ub whereas MDMXR only contacts Ub via its C-terminal tail 
(Fig. 1a-c). This UbcH5B–Ub binding arrangement is similar to that observed in the 
structures of other homodimeric RING E3-E2–Ub complexes31-33. However, unlike 
homodimeric RING E3s where two molecules of E2–Ub bind, MDM2R-MDMXR 
only binds one molecule of UbcH5B–Ub because MDMX does not bind UbcH5B–
Ub. 
 
Interactions between MDM2R-MDMXR and UbcH5B–Ub 
The structure of UbcH5B–Ub adopts the closed, “folded back” configuration 
similar to those observed in other RING E3-E2–Ub complexes30-37 (Fig. 1a-c) 
suggesting that MDM2R-MDMXR primes Ub for transfer. The closed UbcH5B–Ub 
conformation is stabilized by numerous interactions involving MDM2R-UbcH5B, Ub-
UbcH5B, MDM2R-Ub and Ub-MDMX tail interfaces. The MDM2R-UbcH5B 
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interaction involves UbcH5B’s N-terminal helix, L1 and L2 loops and the 
hydrophobic core of MDM2R centering on I440 (Fig. 1d). Ub-UbcH5B interactions 
include UbcH5B’s 2 contacting Ub’s I44 surface and UbcH5B’s active site residues 
clamping Ub’s C-terminal tail (Fig. 1e). MDM2R-Ub interactions involve MDM2’s 
V477 and Zn2+-ligand H457 and Ub’s L8/I36/L71 surface. Additionally, MDM2’s 
R479, known as the “linchpin Arg”38, forms hydrogen bonds with the carbonyl 
oxygens of UbcH5B’s Q92 and Ub’s R72 and the sidechain of Ub’s Q40 (Fig. 1f). 
These interactions are similar to those observed in other RING E3-E2–Ub 
complexes30-37. MDM2 also contains a short helix that precedes the RING domain, 
where S429 and N433 from this helix contact Ub’s T9/K11 surface (Fig. 1f).  
We mutated a selection of key residues involved in Ub-UbcH5B (N77A, 
D87A, S108R, N114A and D117A in UbcH5B, and I44A and L73D in Ub), MDM2R-
Ub (N433R, V477A and R479A in MDM2, and T9A, I36A and Q40R in Ub) and 
MDM2R-UbcH5B (I440A in MDM2) interfaces and performed single-turnover Ub 
transfer to lysine. All mutants were defective in discharging UbcH5B~Ub suggesting 
that the observed interactions are important for MDM2-MDMX-catalyzed Ub transfer 
(Fig. 1g-i and Supplementary Fig. 1a-f). 
 
The importance of the MDMX C-terminal tail in MDM2-MDMX heterodimer 
E3 defective mutations in the C-terminal tail of MDM2 can be reactivated by 
MDMX19, 20, 39. Our structure shows that the last three residues of MDMX (F488-
I489-A490) play a crucial role in stabilizing the closed UbcH5B–Ub conformation. 
F488 packs against Ub’s G35 surface and A490 is completely buried within the 
MDM2R-Ub interface to support Ub binding (Fig. 2a). This binding mode suggests 
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that MDMX’s C-terminus cannot accommodate extra residues. Furthermore, the 
structure shows that MDM2’s C-terminal tail does not contact UbcH5B–Ub.  
To assess the importance of MDMX’s C-terminus, we mutated F488 to 
histidine and alanine and found both mutants were defective in discharging 
UbcH5B~Ub (Fig. 2b,c and Supplementary Fig. 1g,h). Addition of a hexahistidine 
tag to MDMX’s C-terminus also hindered discharge of UbcH5B~Ub (Fig. 2d and 
Supplementary Fig. 1i,j). However, substitution of the corresponding C-terminal 
residue in MDM2, Y489, to histidine or alanine or addition of a hexahistidine tag to 
MDM2’s C-terminus had a minimal effect (Fig. 2b-d and Supplementary Fig. 1g-j), 
consistent with our structure. Thus, the length of MDMX’s C-terminus impacts 
E2~Ub recruitment by MDM2-MDMX heterodimer. MDMX’s F488-Ub interaction 
is conserved in homodimeric RING E3s such as RNF4 and BIRC731-33 but in these 
examples the C-terminus is only partially buried and introducing exogenous C-
terminal residues minimally affected activity40. 
 
A model for MDM2 homodimer bound to E2~Ub 
 Given that MDMX only contributes to the tail-Ub interaction, we reasoned 
that MDM2’s C-terminus could fulfill this role in the MDM2 homodimer. Indeed, 
substituting MDMX’s C-terminal F488-I489-A490 with MDM2’s C-terminal Y489-
F490-P491 marginally improved MDM2-MDMX’s activity (Fig. 2c and 
Supplementary Fig. 1g,h) suggesting that the MDM2 homodimer likely uses a 
similar mechanism to activate E2~Ub. Since MDM2 and MDMX RING domain 
structures are similar (r.m.s. deviation of 0.44 Å for C atoms) and the NMR 
structure of MDM2RH 29 is similar to MDM2R-MDMXR (r.m.s. deviation of 1.47 Å for 
C atoms), we generated a model of MDM2RH bound to UbcH5B–Ub by 
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superimposition of MDM2R-UbcH5B–Ub from our structure onto MDMXR in the 
MDM2R-MDMXR-UbcH5B–Ub structure (Fig. 3a,b). In this model, each MDM2 
RING domain binds one molecule of UbcH5B–Ub and their C-terminal tails are 
buried within the adjacent MDM2R-Ub interface to support Ub binding.  
 To validate this model, we mutated a selection of key residues in the Ub-
UbcH5B (UbcH5B S108R and Ub I44A), MDM2R-Ub (MDM2 R479A) and Ub-
MDM2 tail (MDM2 Y489A) binding interface and performed UbcH5B~Ub discharge 
assay catalyzed by MDM2 homodimer. All mutants were defective in discharging 
UbcH5B~Ub. Moreover, addition of a C-terminal hexahistidine tag reduced the 
activity (Fig. 3c and Supplementary Fig. 1k,l). Thus, the MDM2 homodimer uses a 
similar mechanism as the MDM2-MDMX heterodimer to activate E2~Ub for 
catalysis. 
 
MDM2 homodimer exhibits higher intrinsic ligase activity  
 The structure of the MDM2R-MDMXR-UbcH5B–Ub complex shows that the 
MDM2-MDMX heterodimer can only recruit one molecule of UbcH5B–Ub at a time 
while the model of the MDM2RH-UbcH5B–Ub complex suggests that the MDM2 
homodimer can bind two molecules of UbcH5B–Ub and perhaps enable transfer of 
two Ub molecules simultaneously. To investigate MDM2RH and MDM2R-MDMXR 
Ub transfer mechanisms, we compared their rate of UbcH5B~Ub discharge. Because 
the MDM2 RING domain is known to form large oligomers and dimers during 
expression and purification from E. coli20, we developed a protocol to purify the 
dimeric fraction of MDM2 RING domain and then performed UbcH5B~Ub discharge 
assay by using fluorescently-labeled Ub for quantification. At the same E3 
concentration, MDM2RH discharged UbcH5B~Ub at a faster rate as compared to 
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MDM2R-MDMXR. When MDM2RH concentration is halved, it displayed a similar 
rate of UbcH5B~Ub discharge as MDM2R-MDMXR (Fig. 3d,e). Thus, MDM2RH 
displays two-fold enhancement in rate as compared to MDM2R-MDMXR. 
 
Engineering MDM2 RING domain lacking ligase activity 
 So far, most studies on MDM2’s ligase-independent regulation of p53 are 
based on MDM2 C464A (or C462A in mouse), a mutant that disrupts the Zn2+-
coordination18, 41-43. This mutation has severe consequences on the RING domain fold 
and hence the ability to homo- or heterodimerize. We sought to design an MDM2 
RING mutant that abrogates the ligase activity while maintaining the RING domain 
fold to study the ligase independent function of MDM2. Our structure and model 
suggest that disrupting the MDM2R-UbcH5B, MDM2R-Ub or MDM2 tail-Ub 
interaction could hamper the ligase activity. Given that MDM2 tail mutants can be 
reactivated by MDMX20, 44, we focused on the MDM2R-UbcH5B and MDM2R-Ub 
interfaces. MDM2 I440 and R479 were chosen because I440 plays the central role in 
E2-binding and R479 helps stabilize the closed E2~Ub conformation. The 
corresponding residue to I440 in BRCA1, I26, has been mutated to alanine and was 
found to be defective in activity in vitro45, 46.  
We mutated MDM2 I440 and R479 to several different amino acid residues 
(I440E, I440A, I440D, I440Y, I440R, I440K, R479A, R479P, R479I, R479G, R479F 
and R479K). The basic and acidic residues are expected to severely impact MDM2R-
UbcH5B hydrophobic interactions whereas residues with no or short sidechains 
should not support interactions initiated by the linchpin Arg. In vitro UbcH5B~Ub 
discharge and UbcH5B–Ub binding assays showed that all MDM2 mutants were 
defective in discharging UbcH5B~Ub compared to the wild type MDM2 
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(Supplementary Fig. 2a). Most I440 variants had no measurable UbcH5B–Ub 
binding affinity except I440Y, which displayed ~60-fold weaker affinity than the wild 
type MDM2 (Supplementary Table 1 and Supplementary Fig. 3a). All R479 
variants bound UbcH5B–Ub with weaker affinities and only R479P mutant displayed 
no measurable binding affinity (Supplementary Table 1 and Supplementary Fig. 
3a). Consistent with UbcH5B–Ub binding properties, MDM2 mutants that exhibited 
no measurable UbcH5B–Ub binding affinity were severely compromised in their p53 
ubiquitination activity in cells, with MDM2 I440K, I440E and R479P mutants 
showing basal p53 ubiquitination levels similar to the empty vector (EV) while 
MDM2 I440A, I440R and I440D displaying trace p53 ubiquitination activity (Fig. 4a, 
b).  
Based on these results, MDM2 I440K, I440E and R479P were selected for 
subsequent analyses. To verify these mutations do not have an impact on MDM2 
homo- or heterodimerization, we performed pull-down experiments in vitro. All GST-
tagged MDM2 variants were able to pull-down their corresponding His-tagged 
MDM2 and MDMX variants, suggesting that these mutants are competent in forming 
MDM2 homodimers and MDM2-MDMX heterodimers (Supplementary Fig. 2b,c). 
Immunoprecipitation results show that all the I440 and R479 mutants retained 
the ability to interact with MDMX in cells (Fig. 4c), while the negative control 
MDM2 C464A did not show any interaction. These results were confirmed by 
showing that wild type MDM2, I440K and I440E mutants can interact with and 
import MDMX into the nucleus (Fig. 4d), while C464A did not relocalize MDMX. 
As expected, all mutants, including C464A mutant, interacted with p53 (Fig. 4e), 
showing that neither an intact RING domain nor the ability of MDM2 to interact with 
the E2~Ub complex is required for the N-terminus of MDM2 to bind to p53. 
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Furthermore, addition of MDMX did not complement the loss of activity in MDM2 
I440K or I440E mutants whereas the defective MDM2 Y489D tail-Ub interaction can 
be restored with MDMX’s tail in the heterodimer (Fig. 4f and Supplementary Fig. 
2d). Together, these results showed that MDM2 I440K, I440E and R479P retain the 
RING domain fold to form homodimers and heterodimers with MDMX, but cannot 
interact with E2~Ub to catalyze ubiquitination. 
 
MDMX RING domain is not optimized for E2~Ub activation 
 To understand the basis for the lack of activity in MDMX we superimposed 
the structure of MDMXR onto MDM2R in our MDM2R-MDMXR-UbcH5B–Ub 
structure to generate a model of MDMXR-UbcH5B–Ub complex. The model showed 
that MDMXR harbors residues that are less optimal in UbcH5B and Ub binding 
compared to MDM2R (Fig. 5a,b). Strikingly, MDMXR lacks the linchpin Arg, and 
instead contains K478, which cannot initiate the same hydrogen bond network as 
MDM2’s R479. Furthermore, the MDMXR-MDMXR dimerization interface is 
suboptimal: the two MDMXR N448 sidechains at this interface potentially clash or 
create an electrostatic repulsion (Fig. 5c). MDM2 contains C449 at this position that 
does not clash with C449 in the MDM2 homodimer model or MDMX’s N448 in 
MDM2-MDMX heterodimer (Fig. 5d,e). 
 We wondered whether substituting N448C and K478R could reactivate 
MDMX’s ligase activity. A similar MDMX mutant harboring N448C with residues 
465-480 replaced with MDM2 sequence was previously shown to promote p53 
ubiquitination and degradation in cells13. MDMX displayed no activity under the 
reaction conditions of our UbcH5B~Ub discharge assay, MDMX N448C showed 
marginal activity, while MDMX K478R massively improved the activity. The 
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MDMX N448C K478R mutant further enhanced the activity (Fig. 5f). To assess 
whether these MDMX variants are active in cells, we performed p53 ubiquitination 
assays by transfecting p53, full-length MDMX variants and His-Ub into U2OS cells. 
MDMX N448C and MDMX K478R exhibited no appreciable activity while MDMX 
N448C K478R displayed modest p53 ubiquitination activity, compared to full-length 
MDM2. Remarkably, when we generated an MDM2-MDMX chimera by replacing 
MDM2’s RING domain with MDMX’s RING domain (1-421: MDM2, 422-490:  
MDMX, “MDM2_XRING”) to avoid the complications of the lack of NLS and NES 
and a shorter acidic domain in MDMX, the N448C K478R mutant exhibited p53 
ubiquitination activity similar to wild type MDM2 (Fig. 5g). Based on the model of 
active E3 dimers, the MDM2 I440 and R479 mutants, which have lost the ability to 
bind E2~Ub, may regain E3 activity by forming a dimer with a binding partner - like 
MDMX or other MDM2 proteins - that retain the ability to bind to the E2~Ub 
complex. To test this hypothesis, MDMX K478R (not chimera) was co-expressed 
with MDM2 I440 mutants. All mutants were reactivated by MDMX K478R but not 
by wild type MDMX (Fig. 5h) and binding analysis showed that MDMX K478R has 
acquired the ability to interact with the UbcH5B–Ub complex (Supplementary Fig. 
3b). The ability of MDMX K478R to bind E2~Ub and dimerize with MDM2 I440 
mutants allows it to ubiquitinate p53 (Fig. 5i). Together, these results showed that 
MDMX RING domain sequence is not optimized for E2~Ub activation and 
highlighted the importance of the linchpin Arg in regulating the ligase activity. 
Moreover, these results are consistent with earlier findings that demonstrated the 
requirement of MDM2 acidic domain in promoting p53 ubiquitination and 
degradation in cells47-49. 
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MDM2 I440 or R479 mutants limit p53 activity 
 To assess the effect of the MDM2 mutants on endogenous p53, we generated 
U2OS cells that were conditionally depleted p53 through use of a doxycycline 
inducible shRNA, then removed endogenous MDM2 from these cells by 
CRISPR/Cas9 followed by stable re-expression of various MDM2 mutants 
(Supplementary Fig. 4a-c). Removal of doxycycline then allowed for the re-
expression of endogenous p53. Expression of wild type MDM2 in this system resulted 
in a clear degradation of p53 compared to EV transfected cells, while – as expected -
the C464A, I440K, I440E and R479P mutants failed to degrade p53 (Fig. 6a,b). 
Interestingly, however, despite failing to target p53 for degradation, the expression of 
the I440 or R479 mutants resulted in a significantly lower activation of the p53 target 
genes including p21, PIG3 and TIGAR, compared to that seen in cells expressing the 
MDM2 C464A mutant (Fig. 6a,b, Fig. 7a, and Supplementary Fig. 5).  
Chromatin immunoprecipitation (ChIP) assays to look for MDM2 at the p21 
promoter showed that although wild type MDM2 expression reduced the overall 
amount of p53 protein, the ratio of p53 to MDM2 at the p21 promoter suggested that 
low levels of both proteins were present. By contrast, although MDM2 C464A 
retained the ability to interact with p53 when co-precipitated in solution (Fig. 4e), this 
interaction was not maintained at the p21 promoter, explaining why MDM2 C464A 
cannot efficiently limit p53 activity. Interestingly, the I440 and R479 mutants were all 
found at the p21 promoter with p53 (Fig. 6c,d), suggesting that their ability to limit 
p53’s transcriptional activity reflects a direct perturbation of the formation of an 
active transcriptional complex at the promoter. In terms of proliferation, in the 
absence of p53 (with doxycycline) all of the cell lines grew at the same rate (Fig. 6e). 
However, following reintroduction of endogenous p53, control cells (lacking MDM2) 
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stopped growing while cells expressing wild type MDM2 continued proliferating (Fig. 
6e). Importantly, despite not targeting p53 for degradation, the ability of the MDM2 
I440 or R479 mutants to restrain p53 activity was sufficient to allow proliferation of 
these cells (Fig. 6e). 
 Next, we monitored the response of cells expressing the I440 or R479 MDM2 
mutants to stress signals that lead to the dissociation of the p53-MDM2 interaction. 
While low levels of Actinomycin D inhibit MDM2 by disrupting nucleoli and 
releasing ribosomal proteins that bind an inhibit MDM250, 51, we used 10 nM 
Actinomycin D, which leads to the phosphorylation of N-terminal residues of p53 and 
loss of MDM2 binding52, 53 (Supplementary Fig. 4d). Although the expression of the 
MDM2 I440 or R479 mutants restrained the activation of p53 target genes similarly to 
the expression of wild type MDM2, cells expressing MDM2 I440 or R479 mutants 
responded more robustly to a 18 hour treatment of Actinomycin D (Fig. 7a-c and 
Supplementary Fig. 6), leading to a higher expression of p53 target genes than that 
seen in cells expressing wild type MDM2 at this time. As expected, Actinomycin D 
increased p53 levels in cells expressing wild type MDM2, but did not affect the 
higher p53 levels in cells expressing the E3 defective MDM2 I440, R479 or C464A 
mutants (Fig. 7b,c). As previously reported54, 55, stabilization of p53 was 
accompanied by a decrease in MDMX levels – a response that was only evident in 
cells expressing wild type MDM2, but not the E3 defective mutant. A time course of 
the response showed that the lack of requirement to stabilize p53 in cells expressing 
MDM2 I440 or R479 correlated with a more rapid increase in expression of p21 and 
PIG3 after Actinomycin D treatment compared to a more gradual increased seen in 
cells expressing MDM2 wild type (Fig. 7b,c). Similar results were obtained in cells 
treated with two other inhibitors of the p53-MDM2 interaction, Nutlin 
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(Supplementary Fig. 6b) and Doxorubicin (Supplementary Fig. 6c). Consistently, 
cells expressing MDM2 I440 or R479 mutants showed a more rapid attenuation of 
cell growth in response to Actinomycin D than cells with wild type MDM2 (Fig. 
7d,e). Therefore, although these MDM2 mutants are unable to control p53 levels, they 
can still repress p53 activity Moreover, the high levels of p53 in cells expressing these 
MDM2 mutants can be more rapidly activated in response to stress than p53 
controlled by wild type MDM2 (which degrades p53), where the p53 protein must 
still accumulate.  
 
  
 16 
Discussion 
 The ability of MDMX to interact with MDM2 through the RING domain has 
been described to both inhibit or enhance MDM2 E3 ligase activity10, 56, 57. Our 
present work provides the structural and mechanistic insights into how MDM2 
homodimer and MDM2-MDMX heterodimer bind and activate E2~Ub for transfer. 
Both the MDM2 homodimer and MDM2-MDMX heterodimer utilize a similar 
mechanism as other RING E3s reported previously30-38, 58, where MDM2 RING-E2, 
MDM2-Ub and Ub-E2 interactions restrain E2~Ub into a closed conformation that 
optimally positions the E2~Ub thioester bond for transfer. Complementing previous 
studies19, 20, 39, we show that the C-terminal tail of MDM2 and MDMX in the MDM2 
homodimer and MDM2-MDMX heterodimer, respectively, and their lengths play a 
critical role in supporting Ub binding. In vivo, a similar C-terminal tail mutant of 
MDM2 was able to control p53 to allow normal development through a mechanism 
that required MDMX heterodimerization21. Surprisingly, although this complex 
retains E3 activity, p53 protein accumulated in some tissues and cells from these 
mice, suggesting that degradation was compromised. While the mechanism of how 
this C-terminal mutant controls p53 under these conditions remains unclear, these 
data are consistent with our observations that MDM2 shows E3 independent functions 
to regulate p53.  
 Our data indicate that despite their apparent structural similarity, MDM2 
homodimer and MDM2-MDMX heterodimer have different ability to transfer Ub due 
to their ability to interact with E2~Ub complexes, and that MDM2 homodimer 
exhibits higher intrinsic ligase activity than MDM2-MDMX heterodimer. This can be 
attributed to the inability of MDMX to recruit E2~Ub therefore halving the amount of 
E2~Ub recruited by a heterodimer (compared to an MDM2 homodimer) or the 
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MDM2 RING domain exhibiting a higher turnover rate in the context of the MDM2 
homodimer. However, the experiments performed here are based on the RING 
domain and the regulation of these complexes by post-translational modification59, 
other domains9, 60 or other protein partners which could favor the activity of the 
MDM2-MDMX heterodimer.  
Consistent with an earlier study showing that replacement of MDMX’s N448 
and residues 465-480 with MDM2’s sequences was able to stimulate MDMX’s ligase 
activity13, we found that substituting MDMX’s N448 and K478 to cysteine and 
arginine, respectively, were sufficient to unmask its ligase activity. The N448C 
mutation enables RING domain homodimerization, thereby allowing MDMX tail-Ub 
interaction, whereas K478R presumably stabilizes the closed E2~Ub conformation as 
observed in our structure. These results further underscore the importance of C-
terminal tail-Ub interaction and the linchpin Arg in modulating the ligase activity.  
 Prior studies have used MDM2 C464A mutant to assess ligase-independent 
functions in regulating p53, but C464A also abolishes the RING domain fold. It is 
therefore not clear whether failure of this mutant (or the mouse equivalent) to control 
p5318 reflects a loss of E3 function, a loss of dimerization or a failure to bind to p53 at 
promoters. We show that MDM2 I440K, I440E and R479P abrogate the interaction 
with E2~Ub complexes and abolish MDM2’s E3 activity, while retaining the ability 
to interact with p53, and to homodimerize or heterodimerize (with MDMX), 
suggesting they retain an intact RING domain fold. These mutants can be localized on 
p21 promoter (via p53) and efficiently reduce p53’s transcriptional activity, allowing 
proliferation but rendering cells hypersensitive to stress. Interestingly, MDM2 C464A 
also retains some effect on cell growth and modestly limits the induction of p53 target 
genes including p21 (Fig. 6a,b), potentially reflecting the ability of this mutant to 
 18 
bind p53 in solution (a summary of the activity of these MDM2 mutants is available 
in Supplementary Table 2). 
Finally, it is possible that targeting the catalytic activity of MDM2 to 
reactivate wild type p53 in tumors (which have elevated levels of stress) could open a 
therapeutic window by avoiding the deleterious on-target side effects of completely 
disrupting the MDM2-p53 interaction in normal tissue. Previous work has described 
small molecule inhibitors of MDM2 that bind to the RING domain, inhibiting the E3 
activity and stabilizing p5361, suggesting that such an approach is feasible.  
 
 
 
 
  
 19 
Data availability 
Coordinates and structure factors for MDM2-MDMX-UbcH5B–Ub complex have 
been deposited in Protein Data Bank under accession code of 5MNJ. All other data 
are available from the corresponding authors upon reasonable request. 
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Figure legends 
Figure 1 Structure of MDM2R-MDMXR-UbcH5B–Ub. (a) Cartoon representation 
of the complex. MDM2R is colored green, MDMXR orange, UbcH5B cyan and Ub 
yellow. UbcH5B–Ub linkage colored in blue, UbcH5B’s 1, L1 and L2 loops, 
MDM2 and MDMX’s C-terminus are indicated. Zinc atoms are depicted in gray 
sphere. (b) Surface representation of the complex, colored and oriented as in a. 
MDMX’s C-terminus is indicated with an arrow. (c) Schematic drawing of the 
complex, colored as in a. The C-terminal tail of Ub is shown as a black line. Last 
three residues of MDM2 and MDMX’s C-terminal tails (Y489-F490-P491 in MDM2 
and F488-I489-A490 in MDMX) are shown as thick dark green and brown lines, 
respectively. (d) Close-up view of MDM2R-UbcH5B interactions. (e) Close-up view 
of Ub-UbcH5B interactions. (f) Close-up view of MDM2R-Ub interactions. Left and 
right panels are related by 90º rotation about the y axis. For d, e and f, key residues 
are shown as sticks and colored as in a. Nitrogen and oxygen atoms are in blue and 
red, respectively. (g,h) Nonreduced SDS-PAGE showing the discharge of 
UbcH5B~Ub variants to L-lysine over time catalyzed by MDM2R-MDMXR. Ub’s 
D58 is not involved in the binding interface and D58A substitution had no effect on 
UbcH5B~Ub discharge. (i) Nonreduced SDS-PAGE showing the discharge of 
UbcH5B~Ub to L-lysine over time catalyzed by MDM2R-MDMXR variants. 
Uncropped gel images are shown in Supplementary Data Set 1. 
 
Figure 2 Importance of MDMX’s C-terminal tail. (a) Close-up view of MDMX’s 
C-terminal tail. Transparent surface representation was shown. Last three C-terminal  
residues (F488-I489-A490) are shown as sticks and colored as in Fig. 1. (b) 
Schematic drawing of the complex showing disruption in MDMX’s C-terminus (left 
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panel) would hinder the activity whereas disruption in MDM2’s C-terminus (right 
panel) would not have any effect. (c, d) Nonreduced SDS-PAGE showing the 
discharge of UbcH5B~Ub to L-lysine over time catalyzed by MDM2R-MDMXR 
variants. Uncropped gel images are shown in Supplementary Data Set 1. 
 
Figure 3 Mechanism of E2~Ub recruitment and activation by MDM2RH. (a) A 
model of MDM2RH bound to UbcH5B–Ub generated by superimposition of MDM2R-
UbcH5B–Ub portion of the structure onto MDMXR in the MDM2R-MDMXR-
UbcH5B–Ub structure. All colorings are as in Fig. 1. (b) Schematic drawing of the 
MDM2RH-UbcH5B–Ub model in a. MDM2RH’s C-terminal tails are shown as thick 
dark green lines. (c) Nonreduced SDS-PAGE showing the discharge of UbcH5B~Ub 
variants to L-lysine over time catalyzed by GST-MDM2 variants. (d) Nonreduced 
SDS-PAGE showing the discharge of fluorescently-labeled UbcH5B~Ub to L-lysine 
over time catalyzed by MDM2RH and MDM2R-MDMXR visualized by InstantBlue 
(top panel) and LI-COR Odyssey scanner (bottom panel). (e) A plot showing the rate 
of the discharge of fluorescently-labeled UbcH5B~Ub to L-lysine in d. The reactions 
were performed in duplicate. Uncropped gel images are shown in Supplementary 
Data Set 1. 
 
Figure 4 Redesigning ligase-dead MDM2 mutants. (a, b) Ubiquitination assay 
showing that MDM2 I440 or R479 mutants abolish or reduce p53 ubiquitination. (c) 
Co-immunoprecipitation assay showing that, unlike the MDM2 C464A mutant, 
MDM2 I440K, I440E and R479P can interact with MDMX. (d) MDMX is a 
cytoplasmic protein and can enter nucleus when dimerized with MDM2. GFP-tagged 
MDMX can be found in the nucleus with MDM2 wild type and I440 mutants, 
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demomstrating dimerization between the two proteins. This function is lost in the 
C464A mutant. Scale bar indicates 10 μm. (e) Co-immunoprecipitation assay showing 
all the MDM2 mutants can interact with p53 in solution. An MDM2 protein lacking 
the p53 binding domain (Δp53BD) was used as a negative control. (f) Ubiquitination 
assay showing that, unlike the C-terminal mutant Y489D, I440 mutants cannot be 
reactivated by MDMX. Uncropped blot images are shown in Supplementary Data 
Set 1. 
 
Figure 5 Reactivation of MDMX’s ligase activity. (a) Structural comparison of 
MDM2R-UbcH5B (left panel) and MDMXR-UbcH5B (right panel) interface. (b) 
Structural comparison of MDM2R-Ub (left panel) and MDMXR-Ub (right panel) 
interface. MDMXR-UbcH5B–Ub model was generated by superimposition of 
MDMXR onto MDM2R in the structure of MDM2R-MDMXR-UbcH5B–Ub complex. 
Residues are shown as sticks and all colorings are as in Fig. 1. (c) A model of 
MDMXR-MDMXR homodimer generated as in a showing the presence of N448 at the 
dimerization interface separated by 2.5 Å. (d) A model of MDM2RH generated as in 
Fig. 3a showing the presence of C449 at the dimerization interface separated by 5.0 
Å. (e) The dimerization interface of MDM2R-MDMXR showing MDM2’s C449 and 
MDMX’s N448 separated by 3.7 Å. (f) Nonreduced SDS-PAGE showing the 
discharge of UbcH5B~Ub to L-lysine over time catalyzed by MDM2R-MDMXR and 
MDMXR variants at 250 nM (top panel) and 2.5 μM (bottom panel). (g) 
Ubiquitination assay showing the double mutation of N448C and K478R in the 
MDM2-MDMX chimera (1-421: MDM2, 422-490:  MDMX, “MDM2_XRING”) is 
sufficient to reactivate MDMX's E3 ligase activity. (h) MDM2 I440 mutants are 
reactivated by MDMX K478R but not by WT MDMX, reflecting the ability of 
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MDMX K478R to interact with UbcH5B–Ub complex and ubiquitinate p53. (i) 
Models illustrating that, unlike the MDM2 C-terminus mutant (Y489D), MDM2 I440 
mutants cannot be reactivated by wild type MDMX (Fig. 4f) because neither MDM2 
I440 mutants nor wild type MDMX recruit the UbcH5B–Ub complex 
(Supplementary Fig. 3). However, these mutants can be reactivated by MDMX 
K478R that binds the UbcH5B–Ub complex (Fig. 6h and Supplementary Fig. 3). 
Red cross indicates the point of mutation. Uncropped gel and blot images are shown 
in Supplementary Data Set 1. 
 
Figure 6 MDM2 I440 and R479 mutants can limit p53 activity. (a, b) Western blot 
analysis showing that although MDM2 I440K, I440E and R479P do not degrade p53, 
induction of p21 and other p53 target genes is attenuated by these mutants. n = 3 
independent experiments. p values: v.s. EV (vertical), v.s. C464A (horizontal). n.s. 
indicates non-significant v.s. EV. (c) ChIP for p53 and MDM2 with quantitative PCR 
for a p53 response element in the p21 promoter (-2350 bp) and a non-specific binding 
region (+50 bp). n = 3 independent experiments (each with 2 technical replicates). p 
values: v.s. EV (ChIP: p53), v.s. C464A (ChIP: MDM2). (d) Ratio of MDM2/p53 on 
the p21 promoter based on the ChIP (Fig. 6c, p21 -2350 No Doxy). MDM2 wild type, 
MDM2 I440 and R479 mutants were found at the p21 promoter with p53.  p values: 
v.s. wild type (vertical), v.s. C464A (horizontal). (e) The inhibition of cell growth 
seen following restoration of p53 by removal of Doxycycline (Doxy)) in MDM2 
knock-out cells was rescued by expressing MDM2 wild type, I440 and R479 mutants. 
n = 3 independent experiments. p values: v.s. C464A. F-statistics and degrees of 
freedom of ANOVAs are reported in Supplementary Table 3. Uncropped blot 
images are shown in Supplementary Data Set 1. 
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Figure 7 MDM2 I440 and R479 mutants can quickly respond to the stress. (a) 
qPCR showing that expression of the indicated p53 target genes is attenuated by 
MDM2 I440K, I440E and R479P, and induced more strongly than in cells expressing 
wild type MDM2 following 18 hours treatment with Actinomycin D (10 nM).  n = 3 
independent experiments. p values: v.s. EV No Doxy (vertical), v.s. wild type No 
Doxy ActD (horizontal). n.s. indicates non-significant v.s.EV No Doxy. (b, c) 
Examples of immunoblots and quantification of replicate blots showing that p21 and 
PIG3 are more rapidly induced in cells expressing MDM2 I440 and R479 mutants 
upon Actinomycin D (10 nM) treatment compared to cells expressing wild type 
MDM2 n = 3 independent experiments. Immunoblots of all samples are available in 
Supplementary Fig. 6a. (d) The indicated cells were treated with vehicle or 10nM 
Actinomycin D for varying times as shown then were fixed and stained 120 hours 
after plating. Cells expressing MDM2 I440 or R479 mutants more rapidly attenuate 
cell growth in comparison to MDM2 wild type. (e) Quantification of cell growth 
experiments. SRB intensity was quantified using ImageJ software. p values: v.s. each 
wild type. n.s. indicates non-significant. n = 5 independent experiments. F-statistics 
and degrees of freedom of ANOVAs are reported in Supplementary Table 3. 
Uncropped blot images are shown in Supplementary Data Set 1. 
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Table 1 Data collection and refinement statistics 
 
 MDM2R-MDMXR-UbcH5B–Ub 
(PDB: 5MNJ) 
Data collection  
Space group P1 
Cell dimensions  
    a, b, c (Å) 54.24, 62.76, 66.35 
 ()  69.83. 69.22, 78.21 
Resolution (Å) 50.5–2.16(2.22–2.16)a 
Rmerge 0.075(0.402) 
I/(I) 6.8(1.4) 
CC1/2 0.992(0.73) 
Completeness (%) 95.3(93.3) 
Redundancy 3.2(2.9) 
  
Refinement  
Resolution (Å) 50.5–2.16 
No. reflections 37881 
Rwork / Rfree 0.190/0.231 
No. atoms  
    Protein 5318 
    Ligand/ion (Zn and SO4)  10 
    Water 77 
B factors  
    Protein 55.1 
    Ligand/ion (Zn and SO4) 51.7 
    Water 52.3 
R.m.s. deviations  
    Bond lengths (Å) 0.008 
    Bond angles () 1.254 
aValues in parentheses are for highest-resolution shell. 
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Online Methods 
Protein preparation 
 All constructs were generated by standard PCR-ligation techniques. All 
proteins are human unless otherwise specified and were expressed in BL21 (DE3) 
cells or BL21 (DE3) RIL (Stratagene). To generate MDM2R-MDMXR (MDM2 428-C 
and MDMX 427-C) for crystallization and assays, MDM2R and MDMXR were cloned 
into the first and second multiple cloning site of a bicistronic vector, RSF_Duet 
(Novagen), respectively, where MDM2R contains an N-terminal 6xHis-tag followed 
by a TEV protease cleavage site. 6xHis-MDM2R-MDMXR was purified by Ni-NTA 
affinity, followed by cation exchange and size exclusion chromatography. All 
MDM2R-MDMXR variants were purified in the same manner (Supplementary Fig. 
7a). To generate C-terminal 6xHis-tagged MDM2R-MDMXR variants, MDM2R and 
MDMXR variants were cloned into pGEX4T1 (GE Healthcare) containing an N-
terminal GST-tag and RSF_Duet containing an N-terminal His-tag. MDM2R-
MDMXR variants were formed by co-expressing GST-MDM2R with His-MDMXR 
variants or GST-MDMXR with His-MDM2R variants and subsequently purified by 
Ni-NTA affinity chromatography, followed by glutathione affinity chromatography 
(Supplementary Fig. 7b). For MDMX reactivation and binding assays, MDMXR 
variants were cloned into pGEX4T1 containing an N-terminal GST-tag followed by a 
TEV protease cleavage site. MDMXR variants were purified by glutathione affinity 
chromatography for binding analyses or released from the beads by incubation with 
TEV overnight, followed by cation exchange chromatography for reactivation assays 
(Supplementary Fig. 7c). For binding analyses and assays, MDM2 398-C variants 
were cloned into pGEX4T1 and purified by glutathione affinity chromatography 
(Supplementary Fig. 7d,e). MDMXR variants (10 M; 100 l) were loaded onto 
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superdex 75 10/300 to assess their dimerization state (Supplementary Fig. 7f). To 
obtain pure MDM2RH for assay, MDM2R was cloned into pGEX4T1 containing an N-
terminal 6xHis-GST-tag followed by a TEV protease cleavage site, expressed in 36 L 
of LB broth, purified by glutathione affinity chromatography and subsequently buffer 
exchanged into 50 mM Tris-HCl, pH 7.6, 0.4 M NaCl, 5 %(v/v) glycerol and 1 mM 
DTT. 6xHis-GST tag was removed by incubation with TEV followed by Ni-NTA 
pass-back. The cleaved MDM2R was further purified by HiLoad 26/600 Superdex 200 
chromatography (Supplementary Fig. 7c and Supplementary Fig. 7g). For 
ubiquitination assays, Arabidopsis thaliana Uba1, UbcH5B variants and Ub variants 
were prepared as described previously34. UbcH5BS22R–Ub and UbcH5B–Ub used for 
crystallization and binding analyses, respectively, were prepared as described 
previously34. To generate fluorescently-labeled Ub, a MHHHHHHCG sequence was 
inserted at the N-terminus of Ub and purified by Ni-NTA affinity and size exclusion 
chromatography in PBS buffer, pH 6.6. The protein was labeled by incubation with 
IRDye® 800CW Maleimide (LI-COR) at a molar ratio of 4:1 (protein:dye) for 2 h at 
22 °C in the dark and subsequently buffer exchanged into 25 mM HEPES, pH 7.0 and 
150 mM NaCl using a Zeba spin desalting column (Thermo Fisher) to remove excess 
dye. Protein concentrations were determined by Bio-RAD protein assay using BSA as 
a standard and Ub concentration was determined as described previously34. All 
MDM2, MDMX and MDM2-MDMX variants were stored in 25 mM Tris-HCl, pH 
7.6, 0.4 M NaCl and 1 mM DTT and other proteins were stored in 25 mM Tris-HCl, 
pH 7.6, 0.15 M NaCl and 1 mM DTT. All plasmids generated for protein expression 
were described in Supplementary Table 4. 
 
Crystallization  
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MDM2R-MDMXR-UbcH5B–Ub complex was obtained by mixing 6xHis-
MDM2R-MDMXR (6.6 mg/ml) and UbcH5BS22R–Ub (20 mg/ml) at a 1:1 molar ratio. 
Crystals were grown at 19 °C by microseeding using the hanging-drop vapor 
diffusion method by mixing the complex with an equal volume of reservoir solution 
containing 0.1 M Tris-HCl, pH 8.5, 0.175 M Li2SO4 and 16-20 %(v/v) PEG 3350.  
The crystals were flash-frozen in 0.1 M Tris-HCl, pH 8.5, 0.175 M Li2SO4, 22 %(v/v) 
PEG 3350 and 20% (v/v) ethylene glycol. Data were collected at beamline I24 at 
Diamond Light Source (DLS). 
 
Structural determination 
 The data were integrated with automated XDS62 and scaled using the CCP4 
program suite63. Initial phases were obtained by molecular replacement with 
PHASER64 using UbcH5B and Ub from PDB 3ZNI30 and MDM2R-MDMXR from 
PDB 3VJF28 as the search models. Two copies of MDM2R-MDMXR-UbcH5B–Ub 
complex were found in the asymmetric unit. The model was built in COOT65 and 
refined using PHENIX66. The complex was refined to a resolution of 2.16 Å and the 
final model contained two copies of UbcH5B (Chains A and E residues 2-147), Ub 
(Chains B and F residues 1–76), MDM2R (Chains C and G residues 428-491) and 
MDMXR (Chains D and H residues 427-490). Residues with no observable side chain 
electron density were built as alanine stub. Details of the refinement statistics are 
shown in Table 1. All figure models were generated using PYMOL (Schrödinger). 
 
Surface Plasmon resonance (SPR) analyses 
All SPR experiments were performed at 25 ºC on a Biacore T200 with a CM-5 
chip (GE Healthcare). GST-MDM2 398-C and GST-MDMXR variants were coupled 
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to CM-5 chips as described previously34. For GST-MDM2 398-C variants, UbcH5B–
Ub variants were serially diluted in running buffer containing 25 mM Tris-HCl, pH 
7.6, 150 mM NaCl, 0.1 mg/ml BSA, 1 mM DTT, 0.005% (v/v) Tween-20 and 300 
μM UbΔGG. UbΔGG was included to saturate UbcH5B’s backside for optimal RING 
E3-UbcH5B–Ub interaction as described previously34. For GST-MDMXR variants, 
UbcH5B–Ub variants were serially diluted in running buffer containing 25 mM Tris-
HCl, pH 7.6, 150 mM NaCl, 0.1 mg/ml BSA, 1 mM DTT and 0.005% (v/v) Tween-
20. Binding was measured at indicated concentration ranges in Supplementary Fig. 3 
in duplicate. Data reported are the difference in SPR signal between GST-MDM2 
398-C or GST-MDMXR variants and GST alone. The data were analyzed by steady-
state affinity analysis using Biacore T200 BIAevaluation software (GE Healthcare) 
and Scrubber2 (BioLogic Software). 
 
Single-turnover lysine discharge assays  
UbcH5B variants (7-10 μM) were charged with Ub variants (20-50 μM) in 
buffer containing 50 mM Tris-HCl, pH 7.6, 50 mM NaCl, 0.5 μM Arabidopsis 
thaliana UBA1 and 1 mg/ml BSA for 20 min at 23 °C and charging was stopped by 
incubating the reaction with 0.01 U/ml apyrase (Sigma) and 30 mM EDTA for 2-3 
min at 23 °C as described previously34. The lysine discharge reactions were then 
initiated by adding a mixture containing 50 mM Tris-HCl, pH 7.6, 50 mM NaCl, 1 
mg/ml BSA, L-lysine (150 mM or 50 mM for Supplementary Fig. 1) and E3 variants 
(as indicated or 0.3 μM in Figs. 1g-i, 2c,d, 3c and Supplementary Fig. 2d; 0.8 μM in 
Supplementary Fig. 1a,c,g,i,k; 0.6 μM in Supplementary Fig. 1e; and 0.25 μM in 
Supplementary Fig. 2a). Final concentrations are in parenthesis. Reactions were 
quenched with SDS loading buffer at the indicated times, resolved by SDS-PAGE and 
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visualized by staining with InstantBlue (Expedeon). For quantification in 
Supplementary Fig. 1, the reactions were performed in triplicate. LI-COR Odyssey 
scanner was used to analyze the stained gels and bands were quantified by using 
Image Studio Lite software (LI-COR Biosciences). The fraction of UbcH5B~Ub left 
was plotted on a bar graph. In Fig. 3d, Fluorescently-labeled Ub was used instead of 
Ub and visualization was performed using a LI-COR Odyssey scanner prior to 
staining with InstantBlue. The fluorescently-labeled UbcH5B~Ub band was 
quantified by using Image Studio Lite software (LI-COR Biosciences). 
 
In vitro pull-down experiments 
 GST-MDM2 398-C variants were co-expressed with the respective His-
MDM2 398-C variants or His-MDMX 383-C as shown in Supplementary 2b,c. Cells 
were harvested, lysed and centrifuge. Lysates were applied onto 400 μl of Ni-NTA 
beads, washed with 25 mM Tris-HCl, pH 7.6, 0.2 M NaCl, 20 mM imidazole and 5 
mM -mercaptoethnaol and eluted with 25 mM Tris-HCl, pH 7.6, 0.2 M NaCl, 200 
mM imidazole and 5 mM -mercaptoethnaol. The eluted product was then applied 
onto 400 μl of glutathione sepharose beads, washed with 50 mM Tris-HCl, pH 7.6, 
0.2 M NaCl, 5 mM DTT and eluted with 50 mM Tris-HCl, pH 7.6, 0.2 M NaCl, 5 
mM DTT and 10 mM glutathione. 3 μg of eluted product was then resolved on the 
SDS-PAGE. For control experiments, GST-MDM2 398-C, His-MDM2 398-C and 
His-MDMX 383-C were expressed individually. The lysates were divided in half, 
applied onto 400 μl of Ni-NTA or glutathione sepharose beads, washed and eluted 
with buffer as above. 3 μg of eluted product or equal volume (for proteins that do not 
bind the beads, but eluted with the same volume) was then resolved on the SDS-
PAGE and visualized by staining with InstantBlue. 
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Cell culture and generation of tetracycline inducible p53 knockdown-MDM2 
knock-out cells 
 Human osteosarcoma U2OS or human embryonic kidney HEK293 cells were 
obtained from ATCC and were cultured in Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 10 % FBS and 2 mM L-Glutamine. All cell lines were 
mycoplasma negative and were authenticated by STR multiplex assay. 
 In the experiments showed in Fig. 6, Fig. 7 and Supplementary Fig. 4-6, 
tetracycline inducible p53 knockdown-MDM2 knock-out cells were used. U2OS cells 
were infected with pLKO tet-on shRNA targeting p53 and selected by puromycin for 
5 days. Knock-down of p53 was confirmed by Western blotting. Doxycycline 
treatment induced shRNA expression and p53 depletion within 48 hours and this 
effect was reversed within 5 days after discontinuing doxycycline treatment 
(Supplementary Fig. 4a). CRISPR/Cas9 vectors targeting the MDM2 p53 binding 
domain was then transiently transfected, clones isolated and CRISPR disruptions 
assessed by Western blotting, then confirmed genomic PCR followed by DNA 
sequencing (Supplementary Fig. 4b,c). 
 Doxycycline was discontinued for 5 days before plating for "No Doxy" 
condition. Plasmids used and target sequences were described in Supplementary 
Tables 4 and 5. 
 
Mutagenesis PCR 
 Plasmids used are described in Supplementary Table 4. All mutations within 
the RING domain of MDM2 and MDMX were generated by site-directed 
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mutagenesis using KOD hot start master mix (Cat. No. 71842, Novagen) and verified 
by DNA sequencing. 
 
Immunoblotting 
 Cells were washed with PBS and proteins were extracted with lysis buffer 
(1 % Triton X-100, 150 mM NaCl and 50 mM Tris-HCl pH8.0), which were then 
centrifuged at 16,100 r.c.f. at 4 °C for 10 minutes. Where appropriate, protein 
concentration in cellular lysate was determined using the BCA protein assay, with 
concentrations normalized to the lowest-concentration sample. Samples were heated 
to 99 °C for 10 minutes with sample buffer (Final concentration: 10 % glycerol, 2 % 
SDS, 62.5 mM Tris-HCl pH6.8 and 5 % 2-mercaptoethanol) before separation by 
SDS-PAGE in a 10 % or 4-12 % bis-tris polyacrylamide gel (Life Technologies) and 
transfer to 0.2 µm nitrocellulose membrane (GE Healthcare). After the transfer, the 
membrane was blocked by TTBS supplemented with 5 % skimmed milk or Odyssey 
blocking buffer (LI-COR) for 1 hour, and was then incubated with primary antibodies 
(Supplementary Table 6) overnight at 4 °C.  
 After this incubation time, the membrane was washed with TTBS and 
incubated with appropriate secondary antibodies (Supplementary Table 6) for 1 hour, 
then washed with TTBS and TBS, and membrane-bound secondary antibodies were 
detected using Odyssey scanner (LI-COR). Images were analyzed by Image Studio 
(LI-COR). 
 Data were normalized to actin expression, as appropriate.  
 
Immunoprecipitation 
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 Proteins were extracted and normalized as described in immunoblotting 
section. Cellular lysates containing 250 μg proteins were incubated with 2 μg of 
appropriate primary antibody (Supplementary Table 6) or control IgG for 1 hour at 
4 °C, and then incubated with Dynabeads protein G magnetic beads overnight at 4 °C 
on the rotator. The immunoprecipitates were washed 3 times with PBS and heated to 
99 °C for 10 minutes with sample buffer. After removing magnetic beads, SDS-
PAGE and membrane transfer were performed as described in immunoblotting 
section.  
 
Ubiquitination assay 
 U2OS cells grown in 100 mm dishes were transiently transfected with various 
plasmids (Supplementary Table 4) using Genejuice transfection reagent (Cat. No. 
70967, Novagen) and cultivated for further 24 hours. Cells were treated for 5 hours 
with proteasome inhibitor MG132 (10 mM) and lysed in UBA buffer (6 M Guanidine 
HCl, 300 mM NaCl and 50 mM phosphate pH 8 supplemented with 100 μg/ml N-
Ethylmaleimide (NEM)). Lysates were boiled at 99 °C for 20 minutes with 1,000 
RPM shake. His-tag pull-down was performed using 50 μl of Dynabeads His-Tag 
Isolation & Pull down Beads (Cat. No. 10104D, Novex) overnight and beads were 
washed with UBA, UBB (3 M Guanidine HCl, 300 mM NaCl and 50 mM phosphate 
pH 8), UBC (300 mM NaCl and 50 mM phosphate pH 8) then PBS, followed by 
SDS–PAGE and Western blotting. 
 Ubiquitinated and input proteins were detected by immunoblotting. 
 
Immunofluorescence 
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 HEK293 cells were grown on 13 mm glass-coverslips (VWR) placed into 6 
well plates. Cells were transfected with MDM2 wild type or mutants and GFP-tagged 
MDMX overnight then washed and fixed with 4 % paraformaldehyde (PFA) (Sigma) 
in PBS for 20 minutes at room temperature and PFA was quenched with 30 mM 
glycine in PBS. Cells were washed and permeabilized with 0.2 % Triton X-100 in 
PBS for 10 minutes at room temperature. Cells were then washed with PBS and 
blocked with 0.5 % BSA in PBS for 3 hours at room temperature and were then 
incubated with MDM2 antibody (Supplementary Table 6) overnight at 4 °C. After 
this incubation time, cells were washed with TTBS and incubated with Alexa568-
conjugated secondary antibody (Supplementary Table 6) for 2 hours, then washed 
with TPBS and then PBS. Coverslips were washed with double-distilled water to 
remove any salt residues and then mounted with VECTASHIELD Mounting Medium 
with DAPI (Vector laboratories). Images were taken using confocal microscope 
Fluoview FV1000 (Olympus). 
 
RNA Extraction and Quantitative Real-Time PCR 
 Cells were grown in 100 mm dishes and RNA was extracted using RNeasy 
Mini Kit (Qiagen) RNA concentration was determined using a Nanodrop 2000c 
(Thermo Scientific). cDNA was synthesized through reverse transcription polymerase 
chain reaction (RT-PCR) from 1 μg RNA using High-capacity RNA-to-cDNA Kit 
(Life Technologies). The quantitative real-time PCR (qPCR) reaction was performed 
with 10 ng of cDNA using Fast SYBR green master mix. Primers used are described 
in Supplementary Table 5. The amount of fluorescent PCR product accumulating 
during the PCR programme (20 sec at 95 °C hot start, 40 cycles of 3 sec denaturing at 
95 °C, 30 sec annealing-elongation at 60 °C) was detected by the ABI 7500 Fast 
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(Thermo scientific). Gene expression was quantified relative to the housekeeping 
gene β-2 microglobulin (B2M) according to the comparative ΔΔCt method.  
 
 
Chromatin Immunoprecipitation (ChIP) 
 Approximately 5 x 107 cells (after 5 days of doxycycline discontinuation, 
where appropriate) were seeded on 150 mm dish. After 2 days, cells were washed and 
fixed in 1 % formaldehyde in serum-free DMEM for 10 min. Cross-linking reaction 
was stopped by adding glycine (final concentration 125 mM) for 5 min. Media was 
completely aspirated and cells were washed 4 times with ice cold PBS.  Cells were 
then harvested in 5 ml of ChIP cell lysis buffer (10 mM Tris-HCl pH 8.0, 10 mM 
NaCl, 0.20 % Igepal CA-630, 10 mM NaBu, 50 μg/ml PMSF and 1 μg/ml Leupeptin) 
and incubated for 10 min on ice. Cells were then centrifuged at 2,500 rpm for 5 min at 
4 °C and nuclei was resuspended and incubated in 1.2 ml of ChIP nuclei lysis buffer 
(NLB: 50 mM Tris-HCl pH 8.0, 10 mM EDTA, 1 % SDS, 10 mM NaBu, 50 μg/ml 
PMSF and 1 μg/ml Leupeptin) for 10 min on ice. 0.72 ml of IP dilution buffer (IPDB: 
20 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 1 % Triton X-100, 0.01% SDS, 10 
mM NaBu, 50 μg/ml PMSF and 1 μg/ml Leupeptin) and samples were sonicated 
using the Bioruptor sonicator (high setting, 30s on-30s off) for 30 min (replaced ice 
every 10 min). 4.1 ml of IPDB was added and chromatin was precleared by 20 μl of 
normal mouse IgG (Santa Cruz Biotechnology) and 50 μl of Dynabeads protein G 
(Life technologies) for 4 hours on a rotating wheel at 4 °C. Modified IPDB 
(IPDBmod) was made by combining 1:4 NLB:IPDM. Supernatant was transferred to 
new Eppendorf tubes and set up in necessary conditions for ChIP with p53 and 
MDM2. Samples were incubated on a rotating wheel overnight at 4 °C. 
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ChIP Target conditions 
p53: 0.675 ml chromatin + 0.675 ml IPDBmod + 7.5 μg p53 antibody (DO-1) 
MDM2: 0.675 ml chromatin + 0.675 ml IPDBmod + 7.5 μg MDM2 antibody (Ab-1) 
Negative control: 0.675 ml chromatin + 0.675 ml IPDBmod + 7.5 μg IgG 
 50 μl of Dynabeads protein G was added to the samples and they were 
incubated for 3 hours on a rotating wheel overnight at 4 °C. Beads were washed twice 
with IP wash buffer 1 (20 mM Tris-HCl pH8.0, 50 mM NaCl, 2 mM EDTA, 1 % 
Triton X-100 and 0.001 % SDS), once with IP wash buffer 2 (10 mM Tris-HCl pH8.0, 
250 mM LiCl, 1 mM EDTA, 1 % Igepal CA-630 and 1% Deoxycholate), then twice 
with TE buffer pH8.0. ChIP materials were eluted in 300 μl of ChIP elution buffer 
(100 mM NaHCO3, 1% SDS, 20 μg RNase and 40 μg Proteinase K) on a 
Thermomixer heat block (Eppendorf) at 900 rpm overnight for 65 °C. Input samples 
were similarly processed. 
 Following this, 200 μl of samples were transferred to fresh Eppendorf tubes 
and 200 μl of TE buffer. 400 μl of phenol-chloroform-isoamylalcohol (PCI) was 
added to the samples and they were transferred to the phase-lock tubes (5 Prime) for 
DNA isolation. Samples were spun at 14,000 r.c.f. for 5 minutes at RT and upper 
phase was transferred to Eppendorf tubes. 16 μl of 5 M NaCl and 8 μl of glycogen (5 
mg/ml) was added and vortexed. 1 ml of ice cold 100 % ethanol was then added to the 
samples, voetexed and stored at -80 °C for 30 min. Following this, samples were spun 
at 16,100 r.c.f. for 15 min at 4 °C, and the supernatant was discarded. Pellets were 
washed with 1 ml ice cold 80 % ethanol and spun at 16,100 r.c.f. for 10 min at 4 °C. 
The supernatant was discarded and pellets were dried at RT then DNA was eluted in 
50 μl 10 mM Tris-HCl and heated on a Thermomixer heat block (Eppendorf) for 10 
min at 50 °C in order to dissolve the pellet. Samples were then analyzed via qPCR as 
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described with a modified PCR programme (20 sec at 95 °C hot start, 45 cycles of 3 
sec denaturing at 95 °C, 30 sec annealing-elongation at 60 °C). Primers used are 
provided in Supplementary Table 5. Values were calculated as % input.  
 
Cell growth assay and cell staining 
 Cells were plated in 24-well plates (after 5 days of doxycycline 
discontinuation where appropriate). After trypsinization, the number of viable cells 
was counted using CASY cell counter. 
 For cell staining, cells were fixed with ice-cold 100 % methanol and stained 
with 0.04 % SRB (Sulforhodamine B) in 1 % acetic acid. SRB intensity was 
quantified by ImageJ software. 
 
Statistical analysis and reproducibility 
 Experimental data are expressed as mean ± S.D. unless otherwise indicted. 
Statistical differences were analyzed by one- or two-way analysis of variance 
(ANOVA) followed by Tukey's post-hoc test (two-tailed), as appropriate. F statistics 
and degrees of freedom for all ANOVAs were reported in Supplementary Table 3. 
All statistical analyses were performed with Prism (GraphPad Software). Statistical 
significance was defined as p<0.05. Each experiment was repeated independently at 
least three times and sample sizes and number of repeats are defined in each figure 
legend. 
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Supplementary Table 1 Dissociation constants (Kd) for interactions between MDM2 
variants and UbcH5B–Ub 
Immobilized Protein Analyte Kd (µM) 
MDM2 398-C UbcH5B–Ub + UbΔGG 1.2 ± 0.2 
MDM2 398-C I440E UbcH5B–Ub + UbΔGG N.M. 
MDM2 398-C I440A UbcH5B–Ub + UbΔGG N.M. 
MDM2 398-C I440D UbcH5B–Ub + UbΔGG N.M. 
MDM2 398-C I440Y UbcH5B–Ub + UbΔGG 71 ± 2 
MDM2 398-C I440R UbcH5B–Ub + UbΔGG N.M. 
MDM2 398-C I440K UbcH5B–Ub + UbΔGG N.M. 
MDM2 398-C R479A UbcH5B–Ub + UbΔGG 32 ± 1 
MDM2 398-C R479P UbcH5B–Ub + UbΔGG N.M. 
MDM2 398-C R479I UbcH5B–Ub + UbΔGG 7 ± 1 
MDM2 398-C R479F UbcH5B–Ub + UbΔGG 41 ± 2 
MDM2 398-C R479K UbcH5B–Ub + UbΔGG 22 ± 2 
MDM2 398-C R479G UbcH5B–Ub + UbΔGG 52 ± 2 
s.e.m. are indicated. N.M. indicates no measurable binding. Representative 
sensorgrams and binding curves are shown in Supplementary Fig. 3a. 
  
Supplementary Table 2 Summary of MDM2 mutants in this study 
*Binding partner including MDMX K478R 
  
MDM2 wild type C464A I440K I440E R479P 
Mutation 
(Structural 
estimation) 
N/A Disrupts 
RING domain 
co-ordination 
Does not interact 
with E2–Ub 
complex 
(Disrupts 
hydrophobic 
interaction) 
Does not interact 
with E2–Ub 
complex 
(Disrupts 
hydrogen bonds) 
Interaction with 
E2–Ub complex 
+++ Not tested - - 
p53 binding +++ ++ +++ +++ 
Dimerization 
with MDMX 
+++ - +++ +++ 
Ubiquitination of 
p53 
+++ - - - 
Inhibition of p53 
activity 
+++ + +++ +++ 
Localization on 
p21 promoter 
(via p53) 
+++ + +++ +++ 
Cell growth +++ + +++ +++ 
p53 activation 
after stress 
Slow N/A Fast Fast 
Reactivation 
(Ubiquitination 
of p53) 
N/A - When dimerized 
with appropriate 
binding partner*  
When dimerized 
with appropriate 
binding partner*  
Supplementary Table 3 ANOVA and the F-statistics 
Figures ANOVA F(DFn, DFd) value 
6b One way F(5, 12) = 21.96 (p53/Actin) 
F(5, 12) = 131.9 (p21/Actin) 
6c Two way F(5, 15) = 2.915 (ChIP:p53) 
F(5, 15) = 8.691 (ChIP:MDM2) 
6d One way F(5, 12) = 17.04 
6e Two way F(5, 60) = 41.74 (No Doxy, main effect of mutants) 
7a Two way F(15, 36) = 5.719 (cdkn1a(p21)) 
F(15, 36) = 2.754 (tigar) 
F(15, 36) = 4.232 (fas) 
7e One way F(5, 24) = 50.50 (ActD 0h treatment) 
F(5, 24) = 35.76 (ActD 24h treatment) 
F(5, 24) = 14.39 (ActD 72h treatment) 
F(5, 24) = 30.38 (ActD 120h treatment) 
Supplementary 
5 
One way F(4, 10) = 13.10 (cdkn1a(p21)) 
F(4, 10) = 16.80 (tigar) 
F(4, 10) = 7.144 (fas) 
F(4, 10) = 12.48 (puma) 
F(4, 10) = 16.16 (phlda3) 
F(4, 10) = 12.11 (pig3) 
F(4, 10) = 11.16 (sestrin2) 
F(4, 10) = 25.14 (gadd45α) 
DFn = degrees	of	freedom	numerator	DFd	=	degrees	of	freedom	denominator 
 
 
  
Supplementary Table 4 Plasmids used in this study 
Expression 
Encode Plasmid Tag Assays Reference 
p53 pCD6 N/A Ubiquitination assay 
Co-IP 
1 
MDM2 
 
pCMV N/A Ubiquitination assay 
Co-IP 
Immunofluorescence 
2 
MDMX pcDNA3.1 Myc Ubiquitination assay 
Co-IP 
3 
MDMX pEGFP-C1 GFP Immunofluorescence 4 
MDM2/MDMX 
chimera  
(1-421: MDM2,  
422-490:  
MDMX) 
pCMV FLAG Ubiquitination assay 
Co-IP 
5 
Ubiquitin pDG268 His 
GFP 
Ubiquitination assay 
 
6 
mCherry 
 
pmCherry-C1 N/A Ubiquitination assay 
Co-IP 
7 
MDM2R and 
MDMXR 
RSF_Duet 
 
His on 
(MDM2R) 
In vitro assay Current 
manuscript 
MDM2R pGEX4T1 GST In vitro assay Current 
manuscript 
MDMXR pGEX4T1 GST In vitro assay Current 
manuscript 
MDM2R  RSF_Duet 
 
His  In vitro assay Current 
manuscript 
MDMXR RSF_Duet 
 
His  In vitro assay Current 
manuscript 
MDM2 398-C pGEX4T1 GST In vitro assay Current 
manuscript 
UbcH5B RSF_Duet N/A In vitro assay 8 
Ub  RSF_Duet His In vitro assay 8 
Point mutation(s) are based on these plasmids 
 
Knock down or knock out 
Function Plasmid  Target sequences 
Tetracycline 
inducible p53 
knockdown 
(shRNA) 
Tet-pLKO-puro GAC TCC AGT GGT AAT CTA C 
CRISPR/Cas9  
MDM2 knock-
out (Guide A) 
pX335-U6-
Chimeric_BB-CBh-
hSpCas9n(D10A) 
ATC GTT TAG TCA TAA TAT AC TGG 
(PAM) 
CRISPR/Cas9  
MDM2 knock-
out (Guide B) 
pX335-U6-
Chimeric_BB-CBh-
hSpCas9n(D10A) 
TAT TGT TCA AAT GAT CTT CT AGG 
(PAM) 
 
Tet-pLKO-puro9 was a gift from Dmitri Wiederschain (Addgene plasmid # 21915) 
pX335-U6-Chimeric_BB-CBh-hSpCas9n(D10A)10 was a gift from Feng Zhang 
(Addgene plasmid # 42335) 	
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Supplementary Table 5 Primers used for qPCR or ChIP (5'-3') 
B2M for 
rev 
GTG CTC GCG CTA CTC TCT C 
GTC AAC TTC AAT GTC GGA T 
CDKN1A (p21) for 
rev 
TGG GAG CGG ATA GAC ACA TC 
GGC TCT CTG CTT GTC ATC CTT 
TIGAR for 
rev 
CGC GTG GAG AAA CAA GAT TT 
CCG TAT TTC CTT TCC CGA AG 
FAS for 
rev 
GTA CGG AGT TGG GGA AGC TC 
AGG GCT TAT GGC AGA ATT GG 
PUMA for 
rev 
GAA TCC ACG GCT TTG GAA AA 
TGG CCA CAC TCA CCA CAA AT 
PHLDA3 for 
rev 
GAC CCT CGT GTC CTA AAC CA 
CTC GTC CAT TCC TTC AGC TC 
PIG3 for 
rev 
TCT CTG AAG CAA CGC TGA AAT TC 
ACG TTC TTC TCC CAG TAG GAT CC 
Sestrin2 for 
rev 
ACT CTG GGG GCT TTG AGT CT 
GTC TTC CAC AAA GCA CAG CA 
GADD45α for 
rev 
CAG AAG ACC GAA AGG ATG GA 
ATC TCT GTC GTC GTC CTC GT 
GADD45β for 
rev 
CGC TGG AAG AGC TCG TGG CG 
ACC ACG CTG TCT GGG TCC ACA T 
p21 -2350 bp 
(promoter) 
for 
rev 
CTG GAC TGG GCA CTC TTG TC 
CCC CTT CCT CAC CTG AAA AC 
p21 +50 bp  
(non specific) 
for 
rev 
GGC ACT CAG AGG AGG TGA GA 
ACC CGC GCA CTT AGA GAC AC 
 	
 
  
Supplementary Table 6 Antibodies used in cell-based experiments 
Primary 
Antibody 
Description Supplier Dilution or 
amount 
p53 mouse monoclonal 
(DO-1) 
Santa Cruz 
Biotechnology 
1:1000 (WB) 
2 μg (IP) 
7.5 μg (ChIP) 
p53 rabbit polyclonal  
(FL-393) 
Santa Cruz 
Biotechnology 
1:1000 (WB) 
 
MDM2 mouse monoclonal 
(Ab-1) 
Calbiochem 1:1000 (WB) 
2 μg (IP) 
1:100 (IF) 
7.5 μg (ChIP) 
MDMX 
 
rabbit polyclonal 
(A300-287A) 
Bethyl Laboratories 1:1000 (WB) 
2 μg (IP) 
MDMX mouse monoclonal 
(8C6) 
EMD Millipore 1:1000 (WB) 
PIG3 
 
rabbit polyclonal 
(PC268) 
Calbiochem 1:1000 (WB) 
TIGAR 
 
mouse monoclonal  
(F-5) 
Santa Cruz 
Biotechnology 
1:1000 (WB) 
BAX 
 
mouse monoclonal 
(D2D) 
Santa Cruz 
Biotechnology 
1:1000 (WB) 
phospho-p53 (S15) 
 
rabbit polyclonal 
(9284) 
Cell Signaling 
Technology 
1:1000 (WB) 
phospho-p53 (S20) rabbit polyclonal 
(9287) 
Cell Signaling 
Technology 
1:1000 (WB) 
Actin 
 
rabbit or goat 
polyclonal (I-19) 
Santa Cruz 
Biotechnology 
1:1000 (WB) 
α Tubulin mouse monoclonal 
(DM1A) 
Santa Cruz 
Biotechnology 
1:1000 (WB) 
mCherry goat polyclonal 
(AB0040) 
Acris Antibodies 1:2500 (WB) 
Secondary 
antibody 
 
Alexa568-conjugated donkey anti mouse Life Technologies 1:200 (IF) 
IRDye 680LT-conjugated secondary 
antibody 
LI-COR 1:10000 (WB) 
IRDye 800CW- conjugated secondary 
antibody 
LI-COR 1:10000 (WB) 
 
WB = Western blotting 
IP = Immunoprecipitation 
IF = Immunofluorescence 
ChIP = Chromatin immunoprecipitation 
 
 
 
 
 
 
 
Supplementary Figure 1 
UbcH5B~Ub discharge catalyzed by MDM2 and MDM2-MDMX 
(a) A representative nonreduced SDS-PAGE showing the effects of UbcH5B mutations in discharging UbcH5B variant~Ub to L-lysine in 
1 min catalyzed by MDM2R-MDMXR. (b) A bar graph showing the fraction of UbcH5B variant~Ub left in a. (c) A representative 
nonreduced SDS-PAGE showing the effects of Ub mutations in discharging UbcH5B~Ub variant to L-lysine in 1 min catalyzed by 
MDM2R-MDMXR. (d) A bar graph showing the fraction of UbcH5B variant~Ub left in c. (e) A representative nonreduced SDS-PAGE 
showing the effects of MDM2 mutations in discharging UbcH5B~Ub to L-lysine in 1 min catalyzed by MDM2R-MDMXR variants. (f) A bar 
graph showing the fraction of UbcH5B~Ub left in e. (g) A representative nonreduced SDS-PAGE showing the discharge of UbcH5B~Ub 
to L-lysine in 1 min catalyzed by MDM2R-MDMXR variants. (h) A bar graph showing the fraction of UbcH5B~Ub left in g. (i) A 
representative nonreduced SDS-PAGE showing the discharge of UbcH5B~Ub to L-lysine in 1 min catalyzed by MDM2R-MDMXR 
variants. (j) A bar graph showing the fraction of UbcH5B~Ub left in i. (k) A representative nonreduced SDS-PAGE showing the 
discharge of UbcH5B~Ub to L-lysine in 1 min catalyzed by GST-MDM2 variants. (l) A bar graph showing the fraction of UbcH5B~Ub left 
in k. Three independent reactions were performed (n=3) and error bars indicate standard deviation. 
 
 
 
Supplementary Figure 2 
Redesigning ligase-dead MDM2 mutants 
(a) Nonreduced SDS-PAGE showing the discharge of UbcH5B~Ub to L-lysine over time catalyzed by MDM2 I440 and R479 variants. 
(b) SDS-PAGE showing the pull-down experiments of GST-MDM2 I440E, I440K and R479P with His-MDM2 I440E, I440K and R479P, 
respectively. GST-MDM2 variant and the corresponding His-MDM2 variant were co-expressed in E. coli and purified by Ni-NTA affinity 
followed by glutathione sepharose affinity chromatography. (c) SDS-PAGE showing the pull-down experiments of GST-MDM2 variants 
with His-MDMX. GST-MDM2 variant and His-MDMX were co-expressed in E. coli and purified by Ni-NTA affinity followed by glutathione 
 
 
sepharose affinity chromatography. (d) Nonreduced SDS-PAGE showing the discharge of UbcH5B~Ub to L-lysine over time catalyzed 
by MDM2-MDMX variants. Asterisks indicate contaminants. 
 
 
 
 
 
 
Supplementary Figure 3 
SPR analyses of MDM2 and MDMX variants binding affinities for UbcH5B–Ub 
(a) Representative sensorgrams (left) and binding curves (right) for GST-MDM2 398-C variants with UbcH5B–Ub in the presence of 
UbGG are shown. Only sensorgram is shown for GST-MDM2 398-C variants that displayed no measurable UbcH5B–Ub binding in the 
presence of UbGG. (b) Representative sensorgrams (left) and binding curves (right) for GST-MDMXR variants with UbcH5B–Ub are 
shown. Wild type MDMX displayed no UbcH5B–Ub binding up to 100 M UbcH5B–Ub whereas both K478R and N448C, K478R 
mutants exhibited UbcH5B–Ub binding. However, Kd could not be estimated due to the weak binding affinity. All experiments in a and b 
were performed in duplicates. 
 
 
 
 
 
Supplementary Figure 4 
Validation of tetracycline inducible p53 knockdown and MDM2 knock-out cells. 
U2OS cells were infected with pLKO tet-on shp53. (a) Western blot showing that doxycycline treatment causes p53 knock-down in 2 
days and this effect can be washed off in 5 days. (b) MDM2 was then disrupted by CRISPR. Immunoblotting showing CRISPR 
disruption (target p53 binding domain) resulted in MDM2 knock-out. (c) Genomic PCR followed by sequencing showing that CRISPR 
disruption (target p53 binding domain) caused MDM2 knock-out. (d) MDM2 knock-out cells were treated with indicated drugs for 4 
hours and phosphorylated p53 (serine 15 and serine 20) are analyzed by western blot.  
 
 
 
Supplementary Figure 5 
MDM2 mutants can limit induction of p53 target genes. 
qPCR showing mRNA expression of p53 target genes (gadd45β is not a p53 target gene) is attenuated by MDM2 I440K, I440E but no t 
by C464A. n = 3 independent experiments each. p values: v.s. EV No Doxy (vertical), v.s. C464A No Doxy (horizontal). n.s. indicates 
non-significant. F-statistics and degrees of freedom of ANOVAs are reported in Supplementary Table 3. 
 
 
 
 
 
Supplementary Figure 6 
MDM2 I440 and R479 mutants can rapidly respond to the stress. 
(a) Immunoblots showing that following wild type p53 re-expression by removal of Doxycycline (Doxy), p21 is more rapidly induced in 
cells expressing MDM2 I440 and R479 in response to Actinomycin D treatment compared to cells expressing wild type MDM2 (see Fig. 
5c). Similar responses in cells treated with 4 μM Nutlin (b) and 1 μM Doxorubicin (c). 
 
 
 
 
 
 
 
Supplementary Figure 7 
Purified proteins used in the assays and size exclusion chromatography profiles 
(a) SDS-PAGE showing MDM2R-MDMXR variants. (b) SDS-PAGE showing GST-MDM2R-His-MDMXR and GST-MDMXR-His-MDM2R 
variants. (c) SDS-PAGE showing MDMXR variants, MDM2R-MDMXR and MDMXRH. (d) SDS-PAGE showing GST-MDMXR variants. (e) 
SDS-PAGE showing GST-MDM2 398-C variants. (f) Superdex 75 10/300 gel filtration chromatography profile of MDM2R-MDMXR and 
MDMXR variants. Full length MDMX has been reported to dimerize with Kd of 1 M (Bista, M. et al., Proceedings of the National 
Academy of Sciences of the United States of America 110, 17814-17819, 2013). To assess the dimerization state of MDMXR variant, 
protein samples (10 M, 100 l) were loaded onto superdex 75 10/300. The dotted line indicates the elution volume of MDM2R-MDMXR 
heterodimer. MDMXR variants containing N448C substitution eluted similar or slightly earlier than this line indicating dimer formation, 
whereas MDMX variants lacking N448C substitution eluted later than this line, presumably exist as monomer. (g) HiLoad 26/600 
Superdex 200 chromatography profile of MDM2RH purification. His-GST-MDM2R was incubated with TEV protease to release His-GST 
tag, followed by Ni-NTA pass-back. The cleaved sample was loaded directly onto HiLoad 26/600 Superdex 200. Trace amount of 
MDM2R was found throughout the elution profile (45-95 ml) with the majority of MDM2R eluted between 95-110 ml consistent with an 
earlier report showing that MDM2R exists as dimer and aggregate (Poyurovsky, M.V. et al Embo Journal 26, 90-101, 2007). MDM2RH 
peak (indicated by arrow) eluted after His-GST peak (indicated by arrow; 50 kDa) was assumed as dimer and was pooled and 
concentrated for activity assay in Fig. 3d. 
 







